

Medical Marijuana Market- New Business Opportunities & Investment Research Report

Global medical marijuana market was valued at US\$ 16.5 Bn in 2020, and is anticipated to surge to US\$ 76.5 Bn by 2031, at CAGR of 14.8% over the forecast period


NEW YORK, UNITED STATES, UNITED STATES, August 22, 2022

/EINPresswire.com/ -- The "global Medical Marijuana Market" is there to witness an irrevocable In Upcoming Years. Innovation in the form of digital tools is the buzzword all across. Even though it's the youth engaging in digital and social platforms, the geriatric population could get benefited by engaging the services therein. Thus, the exponential influx of e-business, online consultations, and booking, door-step delivery are likely to run through the enterprise going forward.

According to a recent study by Persistence Market Research, the global medical marijuana market is expected to witness high growth at a CAGR of around 14.8% and reach US\$ 76.5 Bn by 2031.

Medical marijuana is derived from the Cannabis sativa plant. The three major active compounds of the plant are tetrahydrocannabinol, cannabidiol, and cannabinol. Medical marijuana has various applications in the healthcare and therapeutic field, including treatment or managing pain, treating nausea, muscle spasms, managing anxiety, multiple sclerosis, low appetite, sleep problems, and many others.

Other factors driving demand for medical marijuana include the ability to manage or treat insomnia and epilepsy. According to healthcare specialists, medical marijuana is an effective option to manage sleep-related problems because it restores a person's natural sleep cycle that changes due to today's modern lifestyle.



Get Sample Copy of this Report@ <https://www.persistencemarketresearch.com/samples/13897>

Medical marijuana is also known for its strong anti-inflammatory properties. It can treat inflammation from arthritis as well as degenerative changes in the lumbar, cervical or thoracic spine. Many patients use marijuana to treat their pain caused due to inflammation.

Pharmaceutical companies are focused on getting approvals from different government authorities for the use of medical marijuana for treatment purposes.

- In September 2019, GW Pharmaceuticals received approval from European the Commission for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.
- In October 2021, Canopy Growth Corporation announced a plan to acquire Wana Entity, which is a leading cannabis edibles brand in North America.
- In August 2020, MedReleaf Corp. and BioPharma Services Inc. announced their agreement to conduct clinical research for cannabis and cannabis-derived products.

Company Profiles:

- Aphria Incorporation
- Aurora Cannabis Inc.
- Canopy Growth Corporation
- CANNABIS SATIVA, INC.
- Green Relief Inc.
- GW PHARMACEUTICALS PLC
- Insys Therapeutics, Inc.
- Medical Marijuana, Inc.
- MedReleaf Corporation
- The Peace Naturals Project

Request for Methodology@ <https://www.persistencemarketresearch.com/methodology/13897>

Key Takeaways from Market Study

- The extract form of marijuana is widely used in a wide range of applications in the therapeutic field as compared to dried flowers.
- The pain management segment enjoys a high market share of 48.8%, indicating high demand for medical marijuana in pain management procedures.
- 77.6% market share in the distribution channel segment is held by retail pharmacies, because the market is closely regulated by government authorities.
- The North America market is set to grow 5X by 2031.

“Increasing prevalence of chronic pain and epilepsy and legalization of medical marijuana in developing countries are major factors driving demand,” says a Persistence Market Research

analyst.

Who is Winning?

Leading medical marijuana manufacturers are constantly working toward expanding their product portfolios and market presence through key strategies such as product approvals and distribution and collaboration agreements.

- GW Pharmaceuticals received approval from Australian Therapeutic Goods Administration (TGA) for EPIDYOLEX® (cannabidiol) for the treatment epilepsy (2020). The FDA approved EPIDIOLEX® (cannabidiol) oral solution to treat seizures associated with tuberous sclerosis complex.
- Tilray signed a distribution agreement with great north distributors for adult-use cannabis sales across Canada.

Access Full Report@ <https://www.persistencemarketresearch.com/checkout/13897>

Want More Insights?

Persistence Market Research brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global medical marijuana market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the medical marijuana market. The market is segmented into four parts based on product (dried flowers and extract form), application (pain management, seizure, and others), distribution channel (retail pharmacies and e-Commerce), and seven major regions.

Related Reports:

- [Microbiome Therapeutic Market](#)

Global human microbiome market is estimated to attain US\$ 1.8 Bn by 2026 ending, up from US\$ 360 Mn in 2020, growing at a CAGR of 20% during forecast period of 2021-26.

Persistence Market Research Pvt Ltd Atul Singh

PMR

[email us here](#)

+1 646-568-7751

This press release can be viewed online at: <https://www.einpresswire.com/article/587089876>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.